Gilead Sciences (GILD) 104.37 $GILD
Bristol-Myers' Opdivo Gets Priority Review from the FDA
Zacks Equity Research - Zacks Investment Research - 1 hr 10 mins ago
Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for its immuno-oncology drug, Opdivo, has been accepted with priority review by the FDA.
GILD: 104.37 (+0.56), ABBV: 60.22 (+0.21), ACOR: 37.49 (+0.29), BMY: 65.62 (+0.60)
3 Biotech Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 9:31AM CST
Image by Juliacdrd via pixabay Biotech stocks tend to be a risky breed, since even though they can offer investors strong returns, they usually walk hand in hand with huge volatility. To see this reality in action, look no further than the...
GILD: 104.37 (+0.56), IBB: 328.40 (+3.51), AMGN: 157.77 (+3.27), CELG: 111.04 (+0.90)
AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:27PM CST
AbbVie Inc. (ABBV) announced encouraging new data from its ongoing phase IIIb TOPAZ-II study evaluating hepatitis C virus infection drug, Viekira Pak.
JNJ: 101.33 (+0.11), GILD: 104.37 (+0.56), MRK: 53.67 (-0.03), ABBV: 60.22 (+0.21)
Gilead Sciences (GILD) Stock is the 'Chart of the Day'
at The Street - Mon Nov 16, 11:00AM CST
Gilead Sciences (GILD) stock is the 'Chart of the Day.'
GILD: 104.37 (+0.56)
Gilead's Zydelig(R) Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Business Wire - Mon Nov 16, 8:00AM CST
Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (NASDAQ:GILD) today announced that its Phase 3 Study 115 evaluating Zydelig(R) (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival (PFS) and overall survival (OS) in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session (#LBA-5) at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida taking place December 5-8.
GILD: 104.37 (+0.56)
Better Dividend Stock: Gilead Sciences Inc. vs. Teva Pharmaceutical Industries
Keith Speights, The Motley Fool - Motley Fool - Mon Nov 16, 6:41AM CST
Image source: LendingMemo.com . Healthcare offers plenty of great picks for dividend-oriented investors. And the choices aren't just limited to big pharma stocks. Gilead Sciences , for example, is one of the relatively few biotechs that pays a...
GILD: 104.37 (+0.56), TEVA: 60.16 (+1.35)
5 Drugs That Are the Face of Prescription Drug Reform
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 15, 8:41AM CST
Image source: Flickr user StockMonkeys.com. Think fast: what's the first thing that comes to mind when I say "prescription drugs?" Were you too busy reaching for your wallet to think of anything? Don't worry, you're probably not alone. ...
MNK: 57.32 (+0.10), VRX: 70.37 (-2.95), VRTX: 127.50 (+2.22), GILD: 104.37 (+0.56)
Gilead Presents New Data at The Liver Meeting 2015
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced it will present results from multiple studies of Viread(R) (tenofovir disoproxil fumarate, TDF) 300 mg for the treatment of chronic hepatitis B virus (HBV) infection, as well as new data regarding its investigational agents for HBV and nonviral liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), at The Liver Meeting 2015 taking place November 13-17 in San Francisco.
GILD: 104.37 (+0.56)
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (NASDAQ:GILD) today announced it will present 32 scientific presentations related to its approved medicines and investigational therapies for the treatment of chronic hepatitis C virus (HCV) infection at The Liver Meeting 2015 in San Francisco. Data include results from studies of Harvoni(R) (ledipasvir/sofosbuvir) and Sovaldi(R) (sofosbuvir) that advance the understanding of the profiles of these drugs in several patient populations. Detailed results from the four Phase 3 ASTRAL studies evaluating the company's next potential single tablet regimen - a once-daily combination of velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, with sofosbuvir (SOF) - also will be presented.
GILD: 104.37 (+0.56)
Regeneron Tests Buy Point As New Drug Shows Promise
at Investor's Business Daily - Fri Nov 13, 5:24PM CST
After bouncing back from the biotech sell-off that followed Hillary Clinton's accusations of Big Pharma price gouging, Regeneron Pharmaceuticals (REGN) now faces a new test: resistance at its latest buy point. The maker of Eylea eye injections has...
GILD: 104.37 (+0.56), AMGN: 157.77 (+3.27), SNY: 43.58 (+0.46), REGN: 566.85 (+8.47)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 52.83 (-1.35), SWKS: 77.38 (+2.10), GILD: 104.37 (+0.56), SUNE: 3.10 (-1.46), FB: 104.93 (+0.89), MRK: 53.67 (-0.03), STZ: 137.05 (+1.79), ILMN: 172.54 (+2.43), AAPL: 113.66 (-0.52)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 104.37 (+0.56), MRK: 53.67 (-0.03), ABBV: 60.22 (+0.21), BXLT: 34.15 (-0.33)
Tyco Q4 Earnings In Line with Estimates, Revenues Lag
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:28AM CST
Tyco (TYC) reported fourth-quarter fiscal 2015 adjusted income from continuing operations of 61 cents, in line with the Zacks Consensus Estimate.
TYC: 35.38 (-0.33), GILD: 104.37 (+0.56), LAKE: 12.56 (-0.30), ALRM: 16.75 (+0.20)
Gilead Sciences (GILD) Breaks Through Support at $103.23
Comtex SmarTrend(R) - Fri Nov 13, 9:08AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $105.16 and have already reached the first level of support at $103.23. Investors may be interested in a cross of the next downside pivot targets of $102.22 and $99.28.
GILD: 104.37 (+0.56)
5 Stocks Generating Incredible Return on Assets
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 8:56AM CST
Is EPS really a true measure of profits? Let us show you a much better gauge of a company's profitability: the Return on Assets ratio.
NVO: 53.87 (+0.61), BIDU: 196.76 (-1.96), CBOE: 70.75 (+0.75), PFIE: 1.33 (-0.04), GILD: 104.37 (+0.56), WMT: 60.00 (+2.13)
5 Toxic Stocks to Sell Now
at The Street - Fri Nov 13, 8:45AM CST
Here's a technical look at five stocks that you need to unload from your portfolio.
AMX: 15.88 (-0.13), MDLZ: 43.80 (-0.26), GILD: 104.37 (+0.56), SUNE: 3.11 (-1.45), CHL: 58.53 (-0.25)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 104.37 (+0.56), MRK: 53.67 (-0.03), ABBV: 60.22 (+0.21), BMY: 65.62 (+0.60)
Gilead, Regeneron Stocks Weather Drug Pricing Furor
at Investor's Business Daily - Thu Nov 12, 5:30PM CST
Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry's drug-pricing practices and fears of...
MNK: 57.32 (+0.10), ESRX: 83.97 (-0.69), VRX: 70.37 (-2.95), GILD: 104.37 (+0.56), HZNP: 18.53 (-0.43), SNY: 43.58 (+0.46), REGN: 566.85 (+8.47)
U.S. FDA Approves New Indications for Harvoni(R), Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Business Wire - Thu Nov 12, 4:54PM CST
--- Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis -
GILD: 104.37 (+0.56)
Watch for Gilead Sciences to Potentially Rebound After Falling 2.76% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 4:45PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.16 to a high of $107.10. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $107.03 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 104.37 (+0.56)
Bristol-Myers' Opdivo Gets Priority Review from the FDA
Zacks Equity Research - Zacks Investment Research - 1 hr 10 mins ago
Bristol-Myers Squibb Company (BMY) announced that the supplemental Biologics License Application for its immuno-oncology drug, Opdivo, has been accepted with priority review by the FDA.
GILD: 104.37 (+0.56), ABBV: 60.22 (+0.21), ACOR: 37.49 (+0.29), BMY: 65.62 (+0.60)
3 Biotech Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 9:31AM CST
Image by Juliacdrd via pixabay Biotech stocks tend to be a risky breed, since even though they can offer investors strong returns, they usually walk hand in hand with huge volatility. To see this reality in action, look no further than the...
GILD: 104.37 (+0.56), IBB: 328.40 (+3.51), AMGN: 157.77 (+3.27), CELG: 111.04 (+0.90)
AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:27PM CST
AbbVie Inc. (ABBV) announced encouraging new data from its ongoing phase IIIb TOPAZ-II study evaluating hepatitis C virus infection drug, Viekira Pak.
JNJ: 101.33 (+0.11), GILD: 104.37 (+0.56), MRK: 53.67 (-0.03), ABBV: 60.22 (+0.21)
Gilead Sciences (GILD) Stock is the 'Chart of the Day'
at The Street - Mon Nov 16, 11:00AM CST
Gilead Sciences (GILD) stock is the 'Chart of the Day.'
GILD: 104.37 (+0.56)
Gilead's Zydelig(R) Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Business Wire - Mon Nov 16, 8:00AM CST
Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (NASDAQ:GILD) today announced that its Phase 3 Study 115 evaluating Zydelig(R) (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival (PFS) and overall survival (OS) in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session (#LBA-5) at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida taking place December 5-8.
GILD: 104.37 (+0.56)
Better Dividend Stock: Gilead Sciences Inc. vs. Teva Pharmaceutical Industries
Keith Speights, The Motley Fool - Motley Fool - Mon Nov 16, 6:41AM CST
Image source: LendingMemo.com . Healthcare offers plenty of great picks for dividend-oriented investors. And the choices aren't just limited to big pharma stocks. Gilead Sciences , for example, is one of the relatively few biotechs that pays a...
GILD: 104.37 (+0.56), TEVA: 60.16 (+1.35)
5 Drugs That Are the Face of Prescription Drug Reform
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 15, 8:41AM CST
Image source: Flickr user StockMonkeys.com. Think fast: what's the first thing that comes to mind when I say "prescription drugs?" Were you too busy reaching for your wallet to think of anything? Don't worry, you're probably not alone. ...
MNK: 57.32 (+0.10), VRX: 70.37 (-2.95), VRTX: 127.50 (+2.22), GILD: 104.37 (+0.56)
Gilead Presents New Data at The Liver Meeting 2015
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced it will present results from multiple studies of Viread(R) (tenofovir disoproxil fumarate, TDF) 300 mg for the treatment of chronic hepatitis B virus (HBV) infection, as well as new data regarding its investigational agents for HBV and nonviral liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), at The Liver Meeting 2015 taking place November 13-17 in San Francisco.
GILD: 104.37 (+0.56)
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Business Wire - Sat Nov 14, 8:02AM CST
Gilead Sciences, Inc. (NASDAQ:GILD) today announced it will present 32 scientific presentations related to its approved medicines and investigational therapies for the treatment of chronic hepatitis C virus (HCV) infection at The Liver Meeting 2015 in San Francisco. Data include results from studies of Harvoni(R) (ledipasvir/sofosbuvir) and Sovaldi(R) (sofosbuvir) that advance the understanding of the profiles of these drugs in several patient populations. Detailed results from the four Phase 3 ASTRAL studies evaluating the company's next potential single tablet regimen - a once-daily combination of velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, with sofosbuvir (SOF) - also will be presented.
GILD: 104.37 (+0.56)
Regeneron Tests Buy Point As New Drug Shows Promise
at Investor's Business Daily - Fri Nov 13, 5:24PM CST
After bouncing back from the biotech sell-off that followed Hillary Clinton's accusations of Big Pharma price gouging, Regeneron Pharmaceuticals (REGN) now faces a new test: resistance at its latest buy point. The maker of Eylea eye injections has...
GILD: 104.37 (+0.56), AMGN: 157.77 (+3.27), SNY: 43.58 (+0.46), REGN: 566.85 (+8.47)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 52.83 (-1.35), SWKS: 77.38 (+2.10), GILD: 104.37 (+0.56), SUNE: 3.10 (-1.46), FB: 104.93 (+0.89), MRK: 53.67 (-0.03), STZ: 137.05 (+1.79), ILMN: 172.54 (+2.43), AAPL: 113.66 (-0.52)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 104.37 (+0.56), MRK: 53.67 (-0.03), ABBV: 60.22 (+0.21), BXLT: 34.15 (-0.33)
Tyco Q4 Earnings In Line with Estimates, Revenues Lag
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:28AM CST
Tyco (TYC) reported fourth-quarter fiscal 2015 adjusted income from continuing operations of 61 cents, in line with the Zacks Consensus Estimate.
TYC: 35.38 (-0.33), GILD: 104.37 (+0.56), LAKE: 12.56 (-0.30), ALRM: 16.75 (+0.20)
Gilead Sciences (GILD) Breaks Through Support at $103.23
Comtex SmarTrend(R) - Fri Nov 13, 9:08AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $105.16 and have already reached the first level of support at $103.23. Investors may be interested in a cross of the next downside pivot targets of $102.22 and $99.28.
GILD: 104.37 (+0.56)
5 Stocks Generating Incredible Return on Assets
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 8:56AM CST
Is EPS really a true measure of profits? Let us show you a much better gauge of a company's profitability: the Return on Assets ratio.
NVO: 53.87 (+0.61), BIDU: 196.76 (-1.96), CBOE: 70.75 (+0.75), PFIE: 1.33 (-0.04), GILD: 104.37 (+0.56), WMT: 60.00 (+2.13)
5 Toxic Stocks to Sell Now
at The Street - Fri Nov 13, 8:45AM CST
Here's a technical look at five stocks that you need to unload from your portfolio.
AMX: 15.88 (-0.13), MDLZ: 43.80 (-0.26), GILD: 104.37 (+0.56), SUNE: 3.11 (-1.45), CHL: 58.53 (-0.25)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 104.37 (+0.56), MRK: 53.67 (-0.03), ABBV: 60.22 (+0.21), BMY: 65.62 (+0.60)
Gilead, Regeneron Stocks Weather Drug Pricing Furor
at Investor's Business Daily - Thu Nov 12, 5:30PM CST
Recent weeks have not been friendly to the pharmaceutical industry, with some stocks in the sector such as Valeant Pharmaceuticals (VRX) and Horizon Pharma (HZNP) withering amid criticism over the industry's drug-pricing practices and fears of...
MNK: 57.32 (+0.10), ESRX: 83.97 (-0.69), VRX: 70.37 (-2.95), GILD: 104.37 (+0.56), HZNP: 18.53 (-0.43), SNY: 43.58 (+0.46), REGN: 566.85 (+8.47)
U.S. FDA Approves New Indications for Harvoni(R), Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C
Business Wire - Thu Nov 12, 4:54PM CST
--- Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be Considered for Treatment-Experienced Genotype 1 Patients with Cirrhosis -
GILD: 104.37 (+0.56)
Watch for Gilead Sciences to Potentially Rebound After Falling 2.76% Yesterday
Comtex SmarTrend(R) - Thu Nov 12, 4:45PM CST
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $104.16 to a high of $107.10. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $107.03 on volume of 7.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GILD: 104.37 (+0.56)
